Loading...
•
Dec 31, 2022
Glaukos Q4 2022 Earnings Report
Glaukos' Q4 2022 performance caps off a successful year, despite reimbursement headwinds and a challenging macroeconomic environment.
Key Takeaways
Glaukos Corporation reported net sales of $71.2 million in Q4 2022, a 3% decrease compared to the same period in 2021. The company's gross margin was approximately 76%, and non-GAAP gross margin was approximately 84%. The company introduced 2023 net sales guidance range of $290 million to $295 million.
Net sales reached $71.2 million in Q4 2022.
Glaucoma net sales were $52.9 million, while Corneal Health net sales totaled $18.3 million in Q4 2022.
Gross margin was approximately 76%, and non-GAAP gross margin was approximately 84% in Q4 2022.
The company introduced a 2023 net sales guidance range of $290 million to $295 million.
Revenue by Segment
Forward Guidance
The company expects 2023 net sales to be in the range of $290 million to $295 million based on the latest foreign currency exchange rates.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...